Introduction
Transcatheter repair of severe mitral regurgitation (MR) with the MitraClip system is now an established therapeutic option for patients with anatomically suitable mitral valve and in whom surgery is assessed to be of high risk. 1, 2 Anatomical exclusion criteria have evolved with greater collective experience worldwide. In the seminal EVEREST II trial, anatomical exclusion criteria included the presence of excessively large flail segments, flail gaps, clefts, endocarditis, etc. 3 Rheumatic heart disease (RHD) is often regarded as an exclusion criterion, primarily because RHD typically causes mitral stenosis (MS). We herein report a patient with RHD who had severe MR that was successfully treated with the MitraClip. 
Case presentation
The patient was an 85-year-old male with atrial fibrillation, sick sinus syndrome with a permanent pacemaker, and chronic kidney disease (CKD). He had multiple admissions for heart failure (5 over a 6month period) with the most recent admission being associated with cardiogenic shock requiring inotropic support. He had shortness of breath and chest discomfort on exertion as well as orthopnoea for 1 week. Physical examination showed a pulse rate of 89 b.p.m., blood pressure (BP) of 88/57 mmHg, respiratory rate of 28/min, and 89% oxygen saturation on room air. Auscultation revealed a pansystolic murmur over the apex. He was in heart failure with bibasal lung crepitations and bipedal pitting oedema. Intravenous (IV) dopamine was given to support his BP while using IV furosemide to get him out of fluid overload. Electrocardiogram showed a ventricular paced rhythm. His haemoglobin was 14.7 (14.0-18.0) g/dL and estimated glomerular filtration rate was 27 mL/min/1.73 m 2 (stage 4 CKD). Coronary angiography showed single vessel disease with chronic total occlusion (CTO) of the right coronary artery (RCA) receiving collaterals from the left anterior descending artery.
Echocardiography showed a rheumatic mitral valve with moderately thickened leaflets and restricted mobility of the posterior leaflet in both systole and diastole ( Figure 1A, B , Supplementary material online, Video S1). There was gross mal-coaptation of the mitral valve leaflets ( Figure 1C , D, Supplementary material online, Video S2). This resulted in severe MR (Figure 2A -D, Supplementary material online, Videos S3-S5) with an effective regurgitant orifice area (EROA) of 0.99 cm 2 , regurgitant volume of 65 mls, and systolic flow reversal in the pulmonary veins ( Figure 2E ). The mean mitral valve gradient was 2 mmHg and the mitral valve area by planimetry on 3D was 2.7 cm 2 ( Figure 2F , G). There was rheumatic involvement of the aortic valve with mild aortic stenosis and mild-moderate aortic regurgitation. Tricuspid regurgitation was moderate in severity and the estimated pulmonary artery systolic pressure was 28 mmHg. He had normal left ventricular (LV) dimensions and a LV ejection fraction of 55%. There were no regional wall motion abnormalities. Of special note was the fact that although there was an RCA CTO, the inferior and posterior-basal walls did not demonstrate any wall motion abnormalities. The patient was referred to a cardiac surgeon who assessed him to be of very high surgical risk. His EUROSCORE II was 14.8% and his Society of Thoracic Surgeons (STS) score for mortality was 20.0%. After a Heart Team discussion, he was offered the MitraClip therapy.
The first grasp was performed centrally with careful attention to grasp both leaflets adequately especially since there was a significant gap of 4.1 mm between the leaflet tips. With a single clip, the MR was reduced substantially to 1þ ( Figure 3A online, Video S6 and S7). The pulmonary venous flow now showed systolic predominance ( Figure 3E) . The mean mitral gradient was 3 mmHg at a BP of 126/66 mmHg ( Figure 3F) . The combined planimetered mitral valve orifice area was 0.7 þ 1.3 = 2.0 cm 2 ( Figure 3G) . Arterial BP improved substantially (Figure 4) . Post-procedure, his functional status improved from New York Heart Association Classification IV to II. Five years later, at 90 years of age, he had no further heart failure admissions and the MR remained as mild on echocardiography.
Discussion
To the best of our knowledge, this is the first report of successful treatment of rheumatic MR with the MitraClip system. Absolute contraindications for MitraClip implantation include mean mitral valve gradient > 5 mmHg as well as severe calcification in the grasping area. These features, especially significant MS, are frequently seen in a rheumatic mitral valve and hence RHD is excluded from MitraClip procedures. 4, 5 In the EVEREST II trial, the exclusion criteria included patients with a mitral valve area of <4 cm 2 . The features of rheumatic mitral disease in this patient included the thickened and restricted mitral valve leaflets, with restriction in both systole and diastole. Compared to MR due to other pathologies such as degenerative, functional or MR due to infective endocarditis, MR due to RHD is associated with more restricted posterior leaflet movement. 6 Although there was known coronary artery disease, the patient had normal LV systolic function and there were no regional wall motion abnormalities to account for the restricted posterior leaflets. While most RHD typically present at a younger age, in modern societies, RHD is now uncommon and this elderly patient likely represents a late presentation.
Prior to the procedure, we had anticipated that the large coaptation gap and EROA would mandate at least two clips. However, the MR was dramatically reduced with just one clip. We hypothesized that the thickened and less pliable leaflets resulted in greater coaptation when the leaflets were forcibly coapted by the single MitraClip. Although there was a residual gradient of 4 mmHg, this was felt to be clinically not significant in the context of torrential MR at baseline. His subsequent clinical course of events validated our assessment.
In this case, our primary concern was the possibility of causing significant MS. Fortunately, the patient's baseline mitral valve area was large enough such that the residual mitral valve area was adequate. There was also some concern that the gripper hooks would not allow the MitraClip to adequately grip the leaflets. However, although the leaflets were thickened, they were not very calcified and the thick leaflets ultimately influenced the procedure favourably by enhancing coaptation of the leaflets.
Conclusion
This case demonstrates the possibility of rheumatic MR being treated with the MitraClip system in appropriately selected patients. Significant MS has to be excluded and the Heart team should carefully consider if the benefits of MR reduction is felt to significantly outweigh the risk of MS. More importantly, it illustrates the complexity of the mitral valve and how careful examination of the mechanism of MR can guide therapeutic intervention. 
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